Cargando…
Screening for hepatocellular carcinoma: What is missing?
While there are guidelines from all major liver societies for the screening and management of hepatocellular carcinoma (HCC), many issues remain surrounding the actual practice of screening. This review discusses how to diagnose and screen HCC and more importantly, how well we diagnose and screen fo...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747036/ https://www.ncbi.nlm.nih.gov/pubmed/29404430 http://dx.doi.org/10.1002/hep4.1014 |
_version_ | 1783289211401535488 |
---|---|
author | Mehta, Neil J. Celik, Aygul Dogan Peters, Marion G. |
author_facet | Mehta, Neil J. Celik, Aygul Dogan Peters, Marion G. |
author_sort | Mehta, Neil J. |
collection | PubMed |
description | While there are guidelines from all major liver societies for the screening and management of hepatocellular carcinoma (HCC), many issues remain surrounding the actual practice of screening. This review discusses how to diagnose and screen HCC and more importantly, how well we diagnose and screen for HCC. Improved survival and outcomes after HCC diagnosis depend upon accurate diagnosis of cirrhosis and the timeliness of screening. With all oral direct‐acting antivirals now widely available for hepatitis C, there are increasing numbers of patients who may be cured but are still at risk of HCC. Some uncontrolled studies suggest that direct‐acting antiviral therapy may even increase the risk of HCC. Before we discuss expansion of who should be screened, we need physicians to realize how poorly we screen those patients who are already recommended for screening by guidelines. (Hepatology Communications 2017;1:18–22) |
format | Online Article Text |
id | pubmed-5747036 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-57470362018-02-05 Screening for hepatocellular carcinoma: What is missing? Mehta, Neil J. Celik, Aygul Dogan Peters, Marion G. Hepatol Commun Review Articles While there are guidelines from all major liver societies for the screening and management of hepatocellular carcinoma (HCC), many issues remain surrounding the actual practice of screening. This review discusses how to diagnose and screen HCC and more importantly, how well we diagnose and screen for HCC. Improved survival and outcomes after HCC diagnosis depend upon accurate diagnosis of cirrhosis and the timeliness of screening. With all oral direct‐acting antivirals now widely available for hepatitis C, there are increasing numbers of patients who may be cured but are still at risk of HCC. Some uncontrolled studies suggest that direct‐acting antiviral therapy may even increase the risk of HCC. Before we discuss expansion of who should be screened, we need physicians to realize how poorly we screen those patients who are already recommended for screening by guidelines. (Hepatology Communications 2017;1:18–22) John Wiley and Sons Inc. 2016-12-19 /pmc/articles/PMC5747036/ /pubmed/29404430 http://dx.doi.org/10.1002/hep4.1014 Text en © 2016 The Authors. Hepatology Communications published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs (http://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Review Articles Mehta, Neil J. Celik, Aygul Dogan Peters, Marion G. Screening for hepatocellular carcinoma: What is missing? |
title | Screening for hepatocellular carcinoma: What is missing? |
title_full | Screening for hepatocellular carcinoma: What is missing? |
title_fullStr | Screening for hepatocellular carcinoma: What is missing? |
title_full_unstemmed | Screening for hepatocellular carcinoma: What is missing? |
title_short | Screening for hepatocellular carcinoma: What is missing? |
title_sort | screening for hepatocellular carcinoma: what is missing? |
topic | Review Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5747036/ https://www.ncbi.nlm.nih.gov/pubmed/29404430 http://dx.doi.org/10.1002/hep4.1014 |
work_keys_str_mv | AT mehtaneilj screeningforhepatocellularcarcinomawhatismissing AT celikayguldogan screeningforhepatocellularcarcinomawhatismissing AT petersmariong screeningforhepatocellularcarcinomawhatismissing |